Melissa Baird, the Chief Operating Officer of Hims & Hers Health, Inc. (NYSE:HIMS), has recently sold a significant portion of her holdings in the company. According to a recent SEC filing, Baird sold ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Pfizer clinches the top spot in the competitive 2025 Super Bowl ad race, promising groundbreaking visibility during the big ...

When it comes to achieving healthy body weight, some men might look to what’s average and use that as their goal. For ...

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

From mind-blowing tidal surges to the Earth moving, clichés abound when it comes to orgasms. But we’re not all in the throes of ecstasy. According to digital health platform Hims & Hers’s 2023 report, ...

Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...